GlassScriptPhysician profile
Cecilia Olivas
NPI 1912140245
$1,892.07
in general payments reported to CMS, 2019-2025
21 companies · $819 in 2025
The $819 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.31 · 2022: $144 · 2023: $283 · 2024: $625 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,711 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.20 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $342.11 | 2022-2025 | Nayzilam, Briviact, Fintepla |
| Abbvie INC. | $282.82 | 2024-2025 | |
| Neurelis, INC. | $229.74 | 2024-2025 | Valtoco |
| Genentech USA, INC. | $174.72 | 2023-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Biogen, INC. | $125.30 | 2022-2024 | Vumerity, Spinraza |
| Neurocrine Biosciences, INC. | $82.88 | 2023 | |
| Sk Life Science, INC. | $82.43 | 2023-2025 | Xcopri |
| Medtronic, INC. | $79.35 | 2024 | Percept PC Brainsense |
| Pfizer INC. | $66.16 | 2024-2025 | |
| Janssen Biotech, INC. | $54.96 | 2025 | |
| Emd Serono, INC. | $54.41 | 2023-2024 | Mavenclad |
| Merz Pharmaceuticals, LLC | $49.31 | 2025 | Xeomin, Inbrija |
| Alexion Pharmaceuticals, INC. | $44.60 | 2023-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $41.09 | 2025 | Kisunla |
| Jazz Pharmaceuticals INC. | $40.25 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $31.87 | 2024 | Vyvgart Hytrulo |
| Livanova USA, INC. | $31.31 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Catalyst Pharmaceuticals, INC. | $29.60 | 2023-2024 | Fycompa |
| Biohaven Pharmaceuticals, INC. | $20.31 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $15.41 | 2024 | Dysport |
| Amneal Pharmaceuticals LLC | $13.44 | 2024 | Rytary |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecilia Olivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.